SecBot SecBot
8-K ·Filed Jul 30, 2026

MDGL

MADRIGAL PHARMACEUTICALS, INC.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001628280-26-050775
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong revenue beat and continued patient growth confirm robust commercial execution. The initiation of the MGL-2086 Phase 1 trial and new IP patents extend the pipeline and competitive moat. Traders should watch for continued patient adds and any updates on the F4c outcomes trial as key catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

MGL-2086

● Neutral Named in this 8-K
Impact
Phase
Phase 1
Time to market
Unknown — Phase 1 dosing only began June 2026; Phase 2 anticipated 2027, so approval (if trials succeed) is realistically many years away (early-to-mid 2030s).
Next catalyst
None dated

What to watchDo not trade MDGL on MGL-2086, there is no dated readout to trade; near-term price action will be driven by Rezdiffra's commercial ramp and the 2027 MAESTRO F4c cirrhosis outcomes readout. Watch for (1) any early Phase 1 SAD/MAD data release for MGL-2086 (likely 2027), (2) FDA feedback on the Rezdiffra/MGL-2086 Phase 2 combo design, and (3) progress of rival oral GLP-1s (notably Lilly's orforglipron, the molecule this is derived from), which caps the strategic upside.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$493.11
T+0 close · Jul 30, 2026 · via day close
Latest settled
−11.94%
T+60 · $434.24
Vs SPY
−14.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $493.11entry
  2. T+1 · 4mo ago −5.23%α −5.94% · $467.32
  3. T+5 · 3mo ago +3.50%α −0.12% · $510.36
  4. T+20 · 3mo ago +10.26%α +6.29% · $543.69
  5. T+60 · 25d ago −11.94%α −14.40% · $434.24
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Madrigal Pharmaceuticals reported Q2 2026 Rezdiffra net sales of $364.3M, up 71% YoY, beating consensus revenue estimates. The net loss per share of -$1.99 also beat consensus estimates of -$2.23. The company continues to see strong commercial execution with over 49,000 patients on therapy and advanced its pipeline with MGL-2086 entering Phase 1, reinforcing its leadership in the MASH market.

Key Financial Metrics

EPS
−$1.99
est −$2.23 · +10.8%
Revenue
$364.3M
est $352.5M · +3.4% · +71.2% YoY
Rating
beat

Key Facts

  • Q2 2026 Rezdiffra net sales of $364.3M, up 71% YoY from $212.8M
  • Net loss of $57.9M or -$1.99 per share, beating consensus of -$2.23
  • Over 49,000 patients on Rezdiffra as of June 30, 2026, more than doubling from Q2 2025
  • Cash position of $838.9M as of June 30, 2026
  • MGL-2086 (oral GLP-1) Phase 1 trial dosing initiated in June 2026
  • Three new resmetirom patents issued, including one for F4c cirrhosis

Financial Impact

Revenue beat of $11.8M (3.3%) vs consensus; EPS beat of $0.24 (10.8%) vs consensus

revenueepscash

Risk Factors

  • Operating expenses remain high ($420.6M) as the company invests heavily in commercial and R&D activities
  • Net loss widened YoY despite revenue growth due to increased SG&A and R&D spend
  • Dependence on single product Rezdiffra for revenue

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
87% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-050775
Document: mdgl-20260730.htm0001628280-26-050775
Document: 0001628280-26-050775-index-headers.html0001628280-26-050775
Document: 0001628280-26-050775-index.html0001628280-26-050775
Document: 0001628280-26-050775.txt0001628280-26-050775
8-K Data (Synthetic)0001628280-26-050775

Track record

18 reports on MDGL

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +9.15% at T+5 after the Nov 3, 2026 report. 2 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
  2. Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  3. Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  4. Nov 6, 202610d ago Insider Cluster Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  5. Nov 6, 202610d ago 144 Neutral 2/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  6. Nov 5, 202611d ago Institutional Cluster Mixed 3/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
  7. Nov 5, 202611d ago Press Release Bullish 5/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
  8. Nov 3, 202613d ago 8-K Bullish 7/10 No price data
  9. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $396.32 to $432.60 Now $423.96 +6.97% ▲ +9.15% +9.74% vs SPY
  10. Aug 12, 202613w ago 8-K Neutral 3/10 Entry $536.20 to $540.16 Now $423.96 −20.93% ▲ +0.74% +1.18% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026